CrushSCI.com
239.0Average days
238Median days
92Fastest days
433Longest days
4032025 publications

Paper Review Records

All Paper Review Records

25 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

147 days

PDGF-BB and bFGF repress Kai1 in pericytes through Src–DNMT-associated promoter methylation and lysosomal trafficking

Authors
Cheong-Whan Chae; Taehun Yoon; Yoo-Wook Kwon; Hyo-Soo KimShow moreShow less
Affiliations
1. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; 2. Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea; 3. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of KoreaShow moreShow less
Source PDF DOI Publisher page
249 days

B3GNT9-mediated O-glycosylation reprograms fatty acid metabolism in peroxisomes to promote invasion progression of peritumoral glioma cells

Authors
Zechuan Peng; Jiasheng Zhong; Shengsong Fu; Yunhe Zhao; Jie Liu; Fei Wu; Zetao Chen; Tianwei Wang; Yiquan Ke; Taoliang ChenShow moreShow less
Affiliations
1. Neurosurgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China; 2. Department of Neuro-oncological Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China; 3. National Key Clinical Specialty, Zhujiang Hospital, Southern Medical University, Guangzhou, China; 4. Engineering Research Center of Diagnostic and Therapeutic Technology and Devices for Cerebrovascular Diseases, Ministry of Education, Southern Medical University, Guangzhou, China; 5. Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Southern Medical University, Guangzhou, China; 6. Zhujiang Hospital Institute for Brain Science and Intelligence, Zhujiang Hospital, Southern Medical University, Guangzhou, China; 7. Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
433 days

RHBDL2 promotes cancer stemness and chemoresistance in triple-negative breast cancer through EGFR/PI3K/AKT/mTOR/c-Myc pathway

Authors
Dan Wang; Xing Niu; Jingqi Tian; Ruibin Liu; Yuxuan Song; Dingye Zhang; Junze Dai; Shenglong Li; Xudong ZhuShow moreShow less
Affiliations
1. Department of Breast and Thyroid Surgery, Dalian Economic and Technological Development Zone Hospital, Dalian, China; 2. Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China; 3. China Medical University, Shenyang, China; 4. Department of Hepatopancreatobiliary Surgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China; 5. Liaoning Provincial Key Laboratory of Precision Medicine for Malignant Tumors, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China; 6. Department of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China; 7. State Key Laboratory of Oncology in South China, Guangzhou, China; 8. Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
179 days

Disassembly of PKA holoenzyme organization marks prostate cancer progression

Authors
Tal Benjamin-Zukerman; Ran Katz; Gilat Shimon; Meir Solomon; Mirjam M. Nordling-David; Puspashree Sahoo; Basem Hijazi; Ali Safadi; Ronit IlouzShow moreShow less
Affiliations
1. The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel; 2. Department of Urology, Ziv Medical Center, affiliated with Azrieli Faculty of Medicine in the Galilee, Safed, Israel; 3. The Leslie & Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan, IsraelShow moreShow less
Source PDF DOI Publisher page
313 days

Therapy-induced tumour senescence drives oxaliplatin resistance via ADORA1–dependent palmitic acid metabolic reprogramming in colorectal cancer

Authors
Yuqin Long; Xue Li; Yunxi Zhu; Yang Shen; Xiaotian Zhou; Ziqin Wei; Yin Yue; Jie Zhang; Changhong MiaoShow moreShow less
Affiliations
1. Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China; 2. Shanghai Key Laboratory of Perioperative Stress and Protection, and Shanghai Clinical Research Center for Anesthesiology, Shanghai, China; 3. Department of Anesthesiology, Shanghai Medical College, Fudan University, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
379 days

Stabilization of LTBP2 by SIRT1 promotes EMT and chemosensitivity in cardia gastric adenocarcinoma through TGF-β signaling

Authors
Wang Zhenxiang; Tian Tongguan; Chen Ying; Zhang Yan; Qian Meng; Sun Huihui; Xu Yanping; Xu ShuchangShow moreShow less
Affiliations
1. Department of Gastroenterology, Tongji Institute of Digestive Diseases, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China; 2. Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does ONCOGENE take to review a manuscript?

As of 2026-11-18, CrushSCI has 25 complete review records for ONCOGENE. The fastest paper went from submission to acceptance in 92 days (tRNA-derived small RNAs in tumor microenvironment remodeling: From mechanistic insights to therapeutic perspectives, received 2026-04-21, accepted 2026-07-22); the slowest took 433 days. The average is 239.0 days and the median is 238 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.